Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Stapokibart - KeyMed Biosciences/Shanghai JMT-BIO Technology

Next Previous
Drug Profile

Stapokibart - KeyMed Biosciences/Shanghai JMT-BIO Technology

Alternative Names: Anti-IL-4Rα recombinant fully humanized antibody - KeyMed Biosciences; CM-310; CM310 Recombinant humanized monoclonal antibody injection; IL-4Rα(mAb) - KeyMed Biosciences; Kangyueda; Scipibazumab - KeyMed Biosciences; Stapokibatrt

Latest Information Update: 24 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator KeyMed Biosciences
  • Developer KeyMed Biosciences; Shanghai JMT-BIO Technology
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 4 receptor alpha subunit antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Allergic rhinitis; Atopic dermatitis; Rhinosinusitis
  • Preregistration Prurigo nodularis
  • Phase II/III Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 31 Jul 2026 Phase-III clinical trials in Allergic rhinitis (In children, In adolescents, In adults) in China (SC)
  • 01 Jul 2026 Chengdu Kangnuoxing Biopharma plans a phase III trial for Allergic rhinitis (In children, In adolescents) in China (SC, Injection), in August 2026 (NCT07678931)
  • 08 Jun 2026 Chengdu Kangnuoxing Biopharma plans a phase II trial for Allergic rhinitis (In adolescents) in China (SC, Injection) in June 2026 (NCT07617324)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top